Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Psoriasis

In brief

The study will be conducted in 2 parts (SAD for Part 1 and MAD for Part2). Part 1 is a single-center, randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability, immunogenicity, and PK of HS-20118 after a single oral dose in healthy participants. Part 2 is a multi-center, randomized, double-blind, placebo-controlled, MAD study to evaluate the safety, tolerability, immunogenicity, PK, and PD of HS-20118 after multiple oral doses in patients with moderate to severe plaque psoriasis .

Key facts

Study ID

NCT06846710

Run by

Jiangsu Hansoh Pharmaceutical Co., Ltd.

People needed

132

Starts

2025-05-02

Expected to finish

2027-02-28

Last updated by the study team

2025-08-07

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• For the SAD study:
• Healthy adults aged 18-45 years (inclusive) at the time of signing the informed consent form;
• Male participants weighing ≥ 50 kg and female participants weighing ≥ 45 kg, both ≤ 110 kg; body mass index (weight/square of height (kg/m2)) within the range of 18-28 kg/m2 (inclusive);
• Normal results or abnormal results but without clinical significance in comprehensive examinations, including general physical examination, vital signs, laboratory tests, 12-lead ECG, abdominal color Doppler ultrasound, and chest X-ray from the frontal and lateral position ;
• For the MAD study:
• Male or female participants aged 18-65 years (inclusive) at the time of signing the informed consent form;
• Male participants weighing ≥ 50 kg and female participants weighing ≥ 45 kg, both ≤ 110 kg;
• Chronic plaque psoriasis for at least 6 months with or without psoriatic arthritis;

You may not qualify if…

• For the SAD study:
• Participants with immune-related diseases and medical history at screening;
• Participants with a history of drug or other allergies who are considered by the investigator to be at high risk for participating in this study, or who may be allergic to the investigational medicinal product or any component of the investigational medicinal product as judged by the investigator;
• History of drug abuse within the past 5 years or use of illicit drugs within 3 months before the study; or positive for urine drug screening;
• For the MAD study:
• Guttate psoriasis, pustular psoriasis, erythrodermic psoriasis, drug-induced psoriasis, or other diseases that affect the treatment results;
• Current use of illicit drugs or prior use of illicit drugs within the specific time periods;
• Known history of recurrent or chronic infections, or prior history of chronic or recurrent infections, including but not limited to: chronic renal infection, chronic chest infection (e.g., bronchiectasis), symptomatic urinary tract infection, and open, draining, or infected skin wounds; history of serious infections (e.g., sepsis, pneumonia, and pyelonephritis), or hospitalization or treatment with intravenous antibiotics for infections within 2 months before screening;

Where it is running

• Pacific Clinical Research Network (PCRN), Auckland — Takapuna, Auckland, New Zealand (enrolling)
• Clinitiative - Floridian Clinical Research, LLC — Miami Lakes, Florida, United States
• NuLine Clinical Trial Center (Network) — Pompano Beach, Florida, United States
• Pacific Clinical Research Network (PCRN), Christchurch — Christchurch, Christchurch, New Zealand
• Momentum Clinical Research, Dunedin — Dunedin, Dunedin, New Zealand
• Momentum Clinical Research, Pukekohe — Pukekohe, Pukekohe, New Zealand
• Pacific Clinical Research Network (PCRN), Wellington — Upper Hutt, Upper Hutt, New Zealand
• Kinetic Clinical Research — Anaheim, California, United States
• Momentum Clinical Research, Wellington — Mount Cook, Wellington Region, New Zealand

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.